Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : HighTide Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : HTD1801 (berberine ursodeoxycholate), is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
Product Name : HTD1801
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2022
Lead Product(s) : Berberine Ursodeoxycholate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : HighTide Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...
Product Name : GMRx4
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 20, 2022
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing